Advanced solid tumours
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
Who can joinAdults
Age18+ years
Kind of studyPhase 1: first tests of safety
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Where to go
34 hospitals in India taking patients for this trial.
Omega HospitalVisakhapatnam, Andhra PradeshDirections ↗
Post-Graduate Institute of Medical Education and Research(PGIMER)Chandigarh, ChandigarhDirections ↗
Apollo Hospital International LimitedAhmedabad, GujaratDirections ↗
Universal Superspeciality HospitalSurat, GujaratDirections ↗
Unique Hospital Multispeciality and Research InstituteSurat, GujaratDirections ↗
Kiran Hospital Multi Super Speciality Hospital & Research CentreSurat, GujaratDirections ↗
Pt.B.D Sharma PGIMS RohtakRohtak, HaryanaDirections ↗
Healthcare Global Enterprises LtdBangalore, KarnatakaDirections ↗
Cytecare Hospitals Pvt. LtdBangalore, KarnatakaDirections ↗
Vydehi Institute of Medical Sciences and Research CentreBangalore, KarnatakaDirections ↗
KLEs Dr. Prabhakar Kore Hospital & Medical Research CenterBangalore, KarnatakaDirections ↗
K R HospitalMysore, KarnatakaDirections ↗
Krupamayi HospitalAurangabad, MaharashtraDirections ↗
Kolhapur Cancer CentreKolhāpur, MaharashtraDirections ↗
Kims-Kingsway HospitalsNagpur, MaharashtraDirections ↗
Rhythm Heart And Critical CareNagpur, MaharashtraDirections ↗
Treat Me HospitalNagpur, MaharashtraDirections ↗
Soham HospitalNashik, MaharashtraDirections ↗
HCG Manavata Cancer CentreNashik, MaharashtraDirections ↗
Cancure Day Care CentreNavi Mumbai, MaharashtraDirections ↗
The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)Navi Mumbai, MaharashtraDirections ↗
Grant Medical Foundation Ruby Hall ClinicPune, MaharashtraDirections ↗
Novo Solitaire CarePune, MaharashtraDirections ↗
Onco-Life Cancer CentrePune, MaharashtraDirections ↗
Sunact Cancer Institute Pvt LtdThane, MaharashtraDirections ↗
Max Super Speciality HospitalNew Delhi, New DelhiDirections ↗
All India Institute of Medical SciencesNew Delhi, New DelhiDirections ↗
Sparsh Hospital & Critical care(P) LTDBhubaneswar, OdishaDirections ↗
Jawaharlal Institute of postgraduate medical education and researchPuducherry, PuducherryDirections ↗
Apollo Cancer HospitalHyderabad, TelanganaDirections ↗
Basavatarakam Indo American Cancer Hospital & Research InstituteHyderabad, TelanganaDirections ↗
BP Poddar Hospital & Medical Research LtdKolkata, West BengalDirections ↗
Tata Medical CenterKolkata, West BengalDirections ↗
Chittaranjan National Cancer InstituteKolkata, West BengalDirections ↗
Registry summary (technical)
An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced malignancies will be done to assess AUR107 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.
Sponsor: Aurigene Discovery Technologies Limited
NCT05865002 on ClinicalTrials.gov
Last updated on the registry 17 Apr 2026 · read by us 20 Oct 2026